Staplin, Natalie

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 678

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis

Writing Group for the CKD Prognosis Consortium, Appel, L. J., Grams, M., Woodward, M., Harris, K., Arima, H., Chalmers, J., Yatsuya, H., Tamakoshi, K., Li, Y., et al. (2023) · JAMA

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 396

Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients

Staplin, N., de la Sierra, A., Ruilope, L. M., Emberson, J. R., Vinyoles, E., Gorostidi, M., Ruiz-Hurtado, G., Segura, J., Baigent, C., & Williams, B. (2023) · The Lancet

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 290

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 237

Smoking and adverse outcomes in patients with CKD: The Study of Heart and Renal Protection (SHARP)

Staplin, N., Haynes, R., Herrington, W. G., Reith, C., Cass, A., Fellström, B., Jiang, L., Kasiske, B. L., Krane, V., Levin, A., et al. (2016) · American Journal of Kidney Diseases

Smoking Behavior and CessationChronic Kidney Disease and Diabetes

Cited by 86

Conventional and genetic evidence on the association between adiposity and CKD

Zhu, P., Herrington, W. G., Haynes, R., Emberson, J., Landray, M. J., Sudlow, C. L. M., Woodward, M., Baigent, C., Lewington, S., & Staplin, N. (2021) · Journal of the American Society of Nephrology

Genetic Associations and EpidemiologyChronic Kidney Disease and Diabetes

Cited by 83

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

Vonesh, E., Tighiouart, H., Ying, J., Heerspink, H. L., Lewis, J., Staplin, N., Inker, L., & Greene, T. (2019) · Statistics in Medicine

Statistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference

Cited by 78

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Staplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 74

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 16